Outline of Production

An Outline of Production is the detailed manufacturing protocol for a veterinary biological product. Under 9 CFR 101.3(j), it means: “A detailed protocol of methods of manufacture to be followed in the preparation of a biological product and which may sometimes be referred to as an outline.” This definition concerns U.S. USDA APHIS veterinary biologics.

The word outline can sound like a brief overview. Here, the regulatory definition expressly calls for a detailed protocol. Its practical purpose is to describe how the product is to be prepared, rather than to narrate what happened during one production run. That distinction makes it useful to production, laboratory, quality, and regulatory staff for different reasons: each needs to connect the product's instructions to the work and evidence being reviewed.

Three related definitions help establish the scale of that connection. They are in § 101.3, alongside the Outline definition—not in § 101.2.

• Serial: the total quantity of completed product thoroughly mixed in a single container and identified by a serial number, with the special diluent/desiccated-product combination provision in § 101.3(h).
• Subserial: a properly identified portion of a serial further processed at a different time or under different conditions, as described in § 101.3(i).
• Fraction: a specific antigen, its antibodies, or its antitoxin constituting a component of a biological product, under § 101.3(f).

For practical reading, keep three questions separate: What does the product's protocol prescribe? Which serial or subserial was prepared? What evidence shows how that particular preparation and testing were carried out? One document should not be mistaken for the answer to all three.

Section 114.8 requires an Outline of Production on file with APHIS for each licensed biological product and each biological product authorized for import into the United States for Distribution and Sale. The requirement is product-specific; the imported-product branch is not excluded simply because preparation occurs outside a domestic licensed establishment.

For preparation in a licensed establishment, § 114.8 requires production in accordance with the product's filed Outline, subject to changes that may be required under § 114.8(f). This makes the filed protocol more than an internal reference document. A locally preferred instruction is not, by itself, evidence of what the filed Outline says.

Under § 114.8(a), the Outline is prepared as prescribed in § 114.9 and submitted to APHIS for filing. Once objectionable features have been corrected and APHIS takes no further exceptions, it is approved for filing. APHIS retains one copy and returns one to the licensee or permittee under § 114.8(c).

As an implementation practice, distinguish the filed version from a draft, a proposed revision, and a local working instruction. A useful document index identifies the product, the filed Outline and applicable amended pages, and the working documents that use those instructions. Matching product names or filenames alone is a weak way to establish that relationship.

The clearest functional distinction is protocol versus execution. The Outline states the manufacturing methods to be followed. An executed batch record, used here as a practical record concept, captures the evidence for a particular serial or subserial. Calling an internal form a batch record does not make that form the filed Outline.

A team familiar with FDA master records may recognize the idea of reusable manufacturing instructions. That analogy stops at document function. Do not import drug-record approval roles, signature requirements, retention periods, or reporting clocks merely because a local form looks familiar. For this USDA term, the defining anchors are § 101.3(j) and the filing requirements of § 114.8.

This separation is especially useful during a discrepancy review. A complete-looking executed record cannot establish that the correct protocol was used if its instruction reference is wrong. Conversely, retrieving the correct filed Outline does not establish that a particular serial was prepared or tested accordingly.

The Outline does not displace applicable Standard Requirements. Under § 113.4(a), their test methods and procedures must be followed unless the Administrator grants an exemption and that exemption is noted in the filed Outline. Both conditions matter. A company cannot create its own waiver by entering not applicable in a test register.

Section 113.4(b) requires the test methods and procedures used to evaluate the product to be designated in its Outline. Section 113.5(a) then prohibits release before completion of the tests prescribed in the filed Outline or Standard Requirements to establish the product to be pure, safe, potent, and efficacious.

Section 113.5 also requires a competent manufacturer employee to observe tests during all critical periods. These are the times when specified reactions must occur for proper evaluation. Results of all required tests prescribed in the filed Outline or Standard Requirements must be submitted to APHIS.

If a test is designated inconclusive or No Test and the product is not further tested, § 113.5(d) makes unsatisfactory the final conclusion. A nonfinal designation is therefore not an alternative passing category.

As a practice, use a product-specific test register that points to the applicable requirement, method, designation, reasons where needed, and supporting record. Keep planned repeat testing distinct from completed repeat evidence. Do not overwrite the original designation or use a generic test panel as a substitute for the product's actual requirements.

Under § 114.8(d), each licensee must review each Outline for accuracy and sufficiency at least once a year. Revisions necessary to bring the Outline into compliance with the regulations must be submitted to APHIS. The provision distinguishes the recurring review from submission of necessary revisions; it does not describe an automatic annual rewrite of unchanged content.

A useful implementation review compares the filed protocol with the instructions actually being used, the assigned test methods, and changes being considered. Record the review date, the documents examined, discrepancies found, and the person responsible for follow-up. These review-log fields are recommended controls, not a prescribed form under § 114.8(d).

Section 114.8(e) adds a specific conditional duty. When the Administrator requests a list of licensed products to be continued in production under the referenced provision, the licensee must identify the currently used Outline by its last revision-and-filing date and last licensee-review date. The licensee must also designate the Outline to remain in the active file; if more than one has been filed for a product, only the currently used Outline is included.

The Administrator Can Object After Filing

Under § 114.8(f), information unavailable when the current Outline was filed may lead the Administrator to object to methods or procedures and notify the licensee to modify the Outline. If the licensee does not comply, the Administrator may suspend the product license after affording an opportunity for a hearing. During that suspension, the licensee may not prepare the product until notified that the suspension has been withdrawn.

For document control, keep an internal revision date, a submission date, a filing date, and a review date distinguishable. They answer different questions. A completed local change assessment should not be presented as evidence that APHIS has filed the corresponding revised pages.

Section 114.9 provides applicable preparation directions, including general document requirements and product-specific outline guides. It is not simply permission to submit any document labeled manufacturing protocol. The following is a summary of document controls, not a form-filling tutorial.

• Paper and page layout: the section specifies heavy paper receptive to permanent stamp ink, page numbering, and margins for APHIS stamping.
• Identification: product or component name, establishment license number, and preparation date appear on the cover and each page; the licensee or foreign manufacturer's name appears on the cover.
• Revisions: amended pages identify the pages they supersede and their dates. A separate summary of changes refers to the affected pages, paragraphs, or subparagraphs.
• Signatures: the specified final pages of new or completely rewritten Outlines, and each separately revised page, require the authorized representative's signature. Stamped or facsimile signatures are not acceptable.
• Transmittal: transmittal forms are required for original submissions and subsequent revisions.

Section 114.9(b) also allows a special outline to be required for a component or preparation operation where cross-reference would eliminate repetition. Each special outline must be identified by number and cannot be used until APHIS has accepted and filed it.

As an implementation practice, keep a clear reference map when an Outline uses special outlines. The reviewer should be able to identify which referenced document and revision support the operation without assembling an answer from several uncontrolled copies. A short main document is not necessarily incomplete, but its referenced content must remain understandable as part of the protocol being reviewed.

Formatting and technical content deserve separate checks. Correct pagination does not demonstrate that a local instruction matches the filed method; technical agreement does not eliminate the applicable page, signature, revision, and transmittal requirements.

The filed Outline also matters after initial preparation. Section 114.14 limits expiration-date extensions for a serial or subserial. It does not make redating a routine inventory adjustment.

Unless otherwise provided in the filed Outline, § 114.14(a) prohibits extension in these circumstances:

• All fractions have not been evaluated for potency using the tests designated in the filed Outline in accordance with § 113.4(b).
• The serial or portion has left licensed premises. Product shipped from one licensed premises to another licensed premises is exempt from this particular restriction.
• The serial or portion has already received an expiration-date extension, unless otherwise authorized in accordance with § 114.1.

Under § 114.14(b), APHIS may grant an extension when the licensee's request is supported by valid test data demonstrating that potency meets or exceeds release requirements. The new expiration date is calculated from the date the latest satisfactory potency test was initiated—not merely from the request date or the test's completion date. The extension cannot exceed the maximum dating allowed in the filed Outline.

Approval for redating is also conditional: APHIS may require potency retesting during the extended period and, if the serial is found unsatisfactory, require the licensee to remove it from the market.

For an extension assessment, assemble the relevant Outline provisions, evidence for all fractions, the latest satisfactory potency-test initiation date, prior-extension history, and movement history for the exact quantity under consideration. Treat these as separate questions. A licensed-to-licensed shipment addresses one location restriction; it does not itself establish adequate potency evidence, remove the prior-extension restriction, or grant an extension.

A reviewer examines fictional serial DEMO-26-A on October 20, 2026. The document index points to fictional product OP-DEMO, filed Outline revision 03 dated September 1, 2026, and matching working instructions. For this exercise, all other production evidence and required test results are stipulated complete and satisfactory. The sole unresolved item is one required test designated inconclusive, with its reasons recorded and no repeat result yet available.

Current intact physical inventory is 580 containers: 540 held stock plus 40 retained samples. The full output accounting is 600 containers because it also includes 20 consumed in testing. No distribution or other movement is assumed. A balanced quantity calculation does not resolve the inconclusive test.

1. Retrieve the relevant filed testing provision and applicable Standard Requirement rather than relying on the working form's title.
2. Preserve the inconclusive designation and its recorded reason; identify the applicable basis for any repeat testing.
3. Keep the unresolved item visible to the responsible reviewer. A planned repeat is not a completed satisfactory result.

The exercise does not support release while that required testing remains unresolved. Under § 113.5(d), if the product is not further tested, the inconclusive designation becomes an unsatisfactory final conclusion. The fictional review deliberately ends with that item open rather than inventing a passing result.

For the broader operating workflow, use the veterinary biologics serial-testing and records guide. Keep release and notification decisions with the responsible licensee personnel and quality reviewers; a filed-document reference or completed accounting table should not make those decisions for them.